Tectonic Therapeutic (TECX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.08
- Estimate
- -$1.21
- Surprise
- +10.5%
- Score at report (before → after)
- 5.0 → 5.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Tectonic Therapeutic (TECX) reported a narrower loss than forecast — adjusted EPS of -$1.08 against the -$1.21 estimate (a 10.5% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.0/10) to Sell at 5.1/10 after the report.
Coverage in the report window
- Tectonic Therapeutic, Inc. Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-05
- Tectonic Therapeutic Q3 EPS $(1.08) Beats $(1.33) Estimate — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates TECX Sell at 5.1/10.
3 of the last 4 quarters beat the estimate; this quarter's +10.5% surprise compares with a +4.0% four-quarter average. Next scheduled report: 2027-02-25.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $71.00 vs price $20.64 — ratio 3.4×). Rejected, falling back to technical TP.
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $20.64
- Price target
- $22.65
- Stop
- $19.20
- Upside to target
- +9.7%
Risk check: trading volume is running 1.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
TECX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $403.5M
- P/E (fwd)
- -4.3
- 52-week range
- $16.77–$39.53
- Off 52-week high
- 47.8%
- RSI (14)
- 47
- Volume vs avg
- 1.72×
- Score today
- 5.1/10